Retrospective study compares effectiveness of BTK inhibitors and lenalidomide in improving outcomes for primary CNS lymphoma, indicating a shift in treatment strategies.
These data suggest that BTKi maintenance is a highly effective strategy for newly diagnosed PCNSL, offering prolonged progression-free survival compared with lenalidomide. The significant efficacy of BTKi in both first-line maintenance and second-line salvage settings provides a preliminary basis for re-evaluating current treatment paradigms, pending confirmation by prospective trials.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: